OS Therapies achieves incremental FDA alignment for OST-HER2
OS Therapies says it has achieved incremental alignment with the FDA and accepted an MHRA Project Orbis invitation for its OST-HER2 metastatic osteosarcoma program.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.